Dizal Pharmaceutical Co., Ltd. (SHA: 688192) released its Q3 2026 financial report, posting revenue of RMB 4.770 billion for the first nine months of the year – a 714% year‑on‑year increase – and a net profit of RMB 3.634 billion, marking the company’s first‑ever turn to profitability. The breakout performance was driven by the effectiveness of its global exclusive licensing agreement with AstraZeneca for sunvozertinib (Zegfrovy), under which a USD 600 million upfront payment has been received.
Financial Milestone
| Item | Detail |
|---|---|
| Reporting Period | Q3 2026 / first nine months of 2026 (results released 30 Oct 2026) |
| Revenue (9M 2026) | RMB 4.770 billion, up 714% year‑on‑year |
| Net Profit (9M 2026) | RMB 3.634 billion – first profitable period in company history |
| Licensing Income | USD 600 million upfront payment received from AstraZeneca under the global exclusive license for sunvozertinib (Zegfrovy) |
| R&D Investment (9M 2026) | Approximately RMB 593 million |
Regulatory Milestone – FDA sNDA Acceptance
| Item | Detail |
|---|---|
| Agency | U.S. Food and Drug Administration (FDA) |
| Filing Type | Supplemental New Drug Application (sNDA) – accepted in Q3 2026 |
| Product | Zegfrovy (sunvozertinib), independently developed targeted lung cancer therapy |
| Proposed Indication | First‑line treatment of adult patients with locally advanced or metastatic non‑small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion (exon20ins) mutations |
| Review Decision Date | Not disclosed |
Drug Profile & Pipeline
- Molecule: Sunvozertinib (Zegfrovy) – a novel, independently developed targeted therapy designed to inhibit epidermal growth factor receptor (EGFR) variants bearing exon20ins mutations, a class of alterations historically less responsive to earlier‑generation EGFR inhibitors.
- Unmet Need: EGFR exon20ins NSCLC represents a difficult‑to‑treat molecular subset with limited first‑line options, underpinning the strategic value of the FDA first‑line sNDA.
- Hematologic Oncology – Golidocitinib: Clinical studies advancing in first‑line peripheral T‑cell lymphoma (PTCL); a global multicenter Phase III program underway in relapsed/refractory (r/r) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with exploration in first‑line CLL/SLL; and Phase II/III trials in combination with R‑CHOP for first‑line diffuse large B‑cell lymphoma (DLBCL).
- Hematologic Oncology – GW5282: Phase I/II trials ongoing in relapsed/refractory non‑Hodgkin lymphoma (NHL).
- Solid Tumors – DZD6008: Clinical studies evaluating monotherapy and combination therapy in first‑line and later‑line EGFR‑mutated NSCLC are ongoing.
- Upcoming Catalysts: Relevant research findings will be presented at upcoming international academic conferences.
Market Impact & Outlook
- Balance‑Sheet Transformation: The USD 600 million upfront payment from AstraZeneca materially strengthens Dizal’s cash reserves, providing robust support for the global development and commercialization of its innovative pipeline.
- Profitability Inflection: The swing to a RMB 3.634 billion net profit marks Dizal’s transition from an R&D‑stage innovator to a commercially profitable biopharmaceutical company.
- Global Commercial Reach: The AstraZeneca partnership extends sunvozertinib’s footprint beyond China into worldwide markets, leveraging a global commercial infrastructure.
- U.S. Label Expansion Potential: FDA acceptance of the first‑line sNDA positions Zegfrovy for a potential expansion into the first‑line EGFR exon20ins NSCLC setting in the world’s largest pharmaceutical market.
- Pipeline Diversification: Broad advancement across PTCL, CLL/SLL, DLBCL, NHL, and EGFR‑mutated NSCLC reduces single‑asset concentration and builds multiple future revenue engines.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory timelines, clinical outcomes, and commercial expectations for sunvozertinib and Dizal’s pipeline candidates. Actual results may differ materially due to risks including FDA review outcomes, clinical trial results, partnership performance, and competitive dynamics. Financial figures are as reported in the company’s Q3 2026 disclosure.-Fineline Info & Tech
